Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.92 USD | +1.36% | +2.12% | -31.57% |
May. 31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
May. 24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.57% | 4.9B | |
+0.82% | 91.94B | |
-1.32% | 38.74B | |
+64.96% | 26.66B | |
-13.35% | 15.32B | |
-5.97% | 13.3B | |
-11.38% | 11.65B | |
+173.10% | 10.37B | |
-49.84% | 10.12B | |
+2.25% | 9.06B |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Goldman Sachs Adjusts Price Target on Apellis Pharmaceuticals to $90 From $65, Maintains Buy Rating